



TOP ↑
Industry
NEWS

BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum.



1. [Novo Nordisk to Cut Workforce by 1,000](#)

Novo Nordisk intends to reduce its 42,300-person workforce by approximately 1,000 employees as part of its plan to reduce operating costs as the company says it faces a challenging competitive environment in 2017, especially in the US. The reductions are expected to affect R&D units and headquarter staff functions as well as positions in the global commercial organization. [Read More](#)

2. [AbbVie Opens Small-Molecule Manufacturing Facility in Singapore](#)

AbbVie has opened a small-molecule manufacturing facility in Singapore as part of a combined \$320 million investment to expand small-molecule and biologics manufacturing in Singapore. The facility represents the company's first manufacturing facility in Asia. [Read More](#)

3. [Pfizer Completes \\$14 Billion Acquisition of Medivation](#)

Pfizer has completed its previously announced \$14 billion acquisition of Medivation, a San Francisco-based biopharmaceutical company. With the acquisition, Pfizer gains Xtandi (enzalutamide), a prostate cancer drug, which generated approximately \$2.2 billion in global net sales. Medivation is partnered with Astellas Pharma to develop Xtandi globally and commercialize jointly in the US. [Read More](#)

4. [Amgen, Arrowhead Form RNAi Cardiovascular Pacts in \\$674 Million Deal](#)

Amgen has formed two license and collaboration agreements with Arrowhead Pharmaceuticals, a Pasadena, California-based biotechnology company, to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease using Arrowhead's proprietary subcutaneous RNAi delivery platform in a deal valued up to \$674 million. [Read More](#)

5. [FDA Approves Amgen's Amjevita, a Humira Biosimilar...](#)

The FDA has approved Amgen's Amjevita (adalimumab-atto), a biosimilar to AbbVie's Humira (adalimumab), across all eligible indications of the reference product. Humira, an anti-tumor necrosis factor monoclonal antibody, is AbbVie's top-selling product with global 2015 sales of \$14 billion. [Read More](#)

6. [... And Shire Ends Humira Biosimilar Program, Returns Candidate to Momenta](#)

Shire has decided to terminate its collaboration with Momenta Pharmaceuticals, a Cambridge, Massachusetts-based biotechnology company, to develop and commercialize a proposed biosimilar candidate referencing AbbVie's Humira (adalimumab). Shire's decision to terminate the collaboration was based on a portfolio assessment following its acquisition of Baxalta in June 2016. [Read More](#)

7. [GlaxoSmithKline Completes Sale of Aspen](#)

GlaxoSmithKline (GSK) has completed the sale of its remaining 28.2 million ordinary shares in Aspen Pharmacore Holdings at a price of South African Rand (ZAR) 300 (\$21.74) per share raising gross proceeds of approximately ZAR 8.470 million (\$614 million). Following settlement of the sale, GSK will no longer hold any shares in Aspen. GSK has been an Aspen shareholder for seven years. [Read More](#)

8. [Endo Names New CEO and President](#)

Endo has named Paul V. Campanelli president and chief executive officer (CEO), effective immediately. Mr. Campanelli currently serves as president of Endo's generic and over-the-counter drugs businesses, Par Pharmaceutical. Campanelli, who will also join Endo's board of directors, succeeds Rajiv De Silva, who has stepped down as president, CEO, and a member of the board.

[Read More](#)

9. [Cambrex to Acquire PharmaCore for \\$25 Million](#)

Cambrex has agreed to acquire PharmaCore for approximately \$25 million to enhance its active pharmaceutical ingredient (API) manufacturing capabilities. PharmaCore develops and produces APIs and intermediates in batch sizes from milligrams to 100 kilograms and is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. [Read More](#)

10. [Sanofi Pasteur Gets US Gov't Funding for Manufacturing Zika Vaccine](#)

Sanofi and its vaccines global business unit, Sanofi Pasteur, have received a \$43.2 million grant from the Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services to fund the manufacture of an inactivated Zika vaccine for Phase II development. [Read More](#)

****Upcoming DCAT Event****

[DCAT After the Show](#)

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org